secwatch / observer
8-K filed February 27, 2024, 6:59 PM ET ticker IPAR CIK 0000822663
earnings confidence high sentiment positive materiality 0.85

Inter Parfums reports record 2023 sales $1.32B, EPS $4.75; ups dividend 20%

INTERPARFUMS INC

2023-FY EPS reported $4.75 revenue$1,317,700,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

INTERPARFUMS INC reported fourth quarter and full year ended December 31, 2023 results: revenue $329 million (Q4) and $1,318 million (FY), net income $10 million (Q4) and $153 million (FY), EPS diluted EPS $0.32 (Q4) and $4.75 (FY).

Period
fourth quarter and full year ended December 31, 2023
Revenue
$329 million (Q4) and $1,318 million (FY)
Net income
$10 million (Q4) and $153 million (FY)
EPS
diluted EPS $0.32 (Q4) and $4.75 (FY)
Result
reported results
Exact text from the filing
EPS $0.32 $0.52 (37%) $4.75 $3.78 26% At comparable foreign currency exchange rates, consolidated net sales for the three months and year ended December 31, 2023, increased 4% and 20%, respectively, compared to the same periods in 2022. Of note, the average dollar/euro exchange rate for the 2023 fourth quarter was 1.08 compared to 1.02 in the fourth
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 1.0

INTERPARFUMS INC reported fiscal year 2024 results: revenue $1.45 billion, EPS diluted EPS of $5.15. Guidance reaffirmed.

Period
fiscal year 2024
Revenue
$1.45 billion
EPS
diluted EPS of $5.15
Guidance
reaffirmed
Result
guidance update
Exact text from the filing
we are reaffirming our 2024 guidance, which calls for net sales of $1.45 billion, resulting in earnings per diluted share of $5.15.
View on SEC.gov

Browse all earnings releases →

INTERPARFUMS INC filing history →

Source: SEC EDGAR
accession 0001753926-24-000400
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.